Estrogen receptors outside the nucleus in breast cancer

Breast Cancer Research and Treatment

Volumn 108, Issue 3, 2008, Pages 351-361

  Levin, Ellis R ^a   Pietras, Richard J ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Breast cancer; EGF receptor; Estrogen receptor; MAP kinase; Proliferation; Signaling

Indexed keywords

ESTROGEN RECEPTOR;

BREAST CANCER; BREAST CARCINOGENESIS; CANCER HORMONE THERAPY; CELL MEMBRANE; CELL NUCLEUS; CYTOPLASM; ESTROGEN ACTIVITY; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

BREAST NEOPLASMS; CELL MEMBRANE; CELL NUCLEUS; FEMALE; HUMANS; MITOCHONDRIA; PROTEIN TRANSPORT; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION;

EID: 41149098579     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-007-9618-4     Document Type: Review

References (126)

1. Jensen EV, Jacobson HI (1962) Basic guides to the mechanism of estrogen action. Rec Prog Horm Res 18:387-414
2. Pietras R, Szego C (1979) Estrogen receptors in uterine plasma membrane. J Steroid Biochem 11:1471-1483
3. Levin ER (2001) Cell Localization, physiology and nongenomic actions of estrogen receptors. J Appl Physiol 91:1860-1867
4. Kushner PJ, Agard D, Feng WJ, Lopez G, Schiau A, Uht R, Webb P, Greene G (2000) Oestrogen receptor function at classical and alternative response elements. Novartis Found Symp 230:20-26
5. Mandava MB (1988) Plant growth-promoting brassinosteroids. Ann Rev Plant Physiol Plant Mol Biol 39:23-52
6. Wang ZY, Seto H, Fujioka S, Yoshida S, Chory J (2001) BRl1 is a critical component of a plasma-membrane receptor for plant steroids. Nature 410:380-383
7. Qin C, Samudio I, Ngwenya S, Safe S (2004) Estrogen-dependent regulation of ornithine decarboxylase in breast cancer cells through activation of nongenomic cAMP-dependent pathways. Mol Carcinog 40:160-170
8. Watters JJ, Chun TY, Kim YN, Bertics PJ, Gorski J (2000) Estrogen modulation of prolactin gene expression requires an intact mitogen-activated protein kinase signal transduction pathway in cultured rat pituitary cells. Mol Endocrinol 14:1872-1881
9. Razandi M, Pedram A, Rosen E, Levin ER (2004) BRCA1 inhibits membrane estrogen and growth factor receptor signaling to cell proliferation in breast cancer. Mol Cell Biol 24:5900-5913
10. Dowsett M, Nicholson R, Pietras R (2005) Biological characteristics of the pure antiestrogen fulvestrant: overcoming endocrine resistance. Breast Cancer Res Treat 93:S11-S118
11. Coombes RC, Hall E, Gibson LJ et al for the Intergroup Exemestane Study (2004) A randomized trial of exemestane after two or three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081-1092
12. Howell A, Cuzick J, Baum M et al for the ATAC Trialists' Group (2005) Results of the ATAC (Arimidex, Tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365:60-62
13. ThŸrlimann B, Keshaviah A, Coates AS et al for the Breast International Group (BIG) 1-98 Collaborative Group (1975) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747-2757
14. Pietras R, Szego C (1975) Endometrial cell calcium and oestrogen action. Nature 253: 357-359
15. Pietras R, Szego C (1977) Specific binding sites for oestrogen at the outer surfaces of isolated endometrial cells. Nature 265:69-72
16. Migliaccio A, Di Domenico M, Castoria G et al (1996) Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO J 15:1292-1300
17. Nemere I, Farach-Carson M (1998) Membrane receptors for steroid hormones: a case for specific cell surface binding sites for vitamin D metabolites and estrogens. Biochem Biophys Res Commun 248:443-449
18. Kelly M, Levin E (2001) Rapid actions of plasma membrane estrogen receptors. Trends Endocrinol Metab 12:152-156
19. Pietras R, Nemere I, Szego C (2001) Steroid hormone receptors in target cell membranes. Endocrine 14:417-427
20. Levin E (2005) Integration of the extra-nuclear and nuclear actions of estrogen. Mol Endocrinol 19:1951-1959
21. Pietras R, Marquez D, Chen H-W et al (2005) Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells. Steroids 70:372-381
22. Green S, Walter P, Kumar V et al (1986) Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature 320:134-139
23. Li L, Haynes M, Bender J (2003) Plasma membrane localization and function of the estrogen receptor alpha variant (ER46) in human endothelial cells. Proc Natl Acad Sci 100:4807-4812
24. Marquez D, Chen H-W, Curran E et al (2006) Estrogen receptors in membrane lipid rafts and signal transduction in breast cancer. Mol Cell Endocrinol 246:91-100
25. Kim R, Kaneko M, Arhiro K et al (2006) Extranuclear expression of hormone receptors in primary breast cancer. Ann Oncol 17:1213-1220
26. Pietras R, Szego C (1980) Partial purification and characterization of oestrogen receptors in subfractions of hepatocyte plasma membrane. Biochem J 191:743-760
27. Pappas TC, Gametchu B, Yannariello-Brown J, Collins TJ, Watson CS (1995) Membrane estrogen receptors identified by multiple antibody labeling and impeded ligand binding. FASEB J 9:404-410
28. Norfleet AM, Thomas ML, Gametchu B, Watson CS (1999) Estrogen receptor-alpha detected on the plasma membrane of aldehyde-fixed GH3/B6/F10 rat pituitary tumor cells by enzyme-linked immunocytochemistry. Endocrinology 140:3805-3814
29. Razandi M, Pedram A, Greene GL, Levin ER (1999) Cell membrane and nuclear estrogen receptors derive from a single transcript: studies of ERα and ERβ expressed in CHO cells. Mol Endocrinol 13:307-319
30. Chambliss KL, Yuhanna IS, Anderson RG, Mendelsohn ME, Shaul PW (2002) ERbeta has nongenomic action in caveolae. Mol Endocrinol 16:938-946
31. Stabile L, Davis A, Gubish C, Hopkins T et al (2002) Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Cancer Res 62:2141-2150
32. Razandi M, Pedram A, Merchenthaler I, Greene GL, Levin ER (2004) Plasma membrane estrogen receptors exist and function as dimers. Mol Endocrinol 18:2854-2865
33. Xiang R, Shi Y, Dillon D et al (2004) 2D LC/MS analysis of membrane proteins from breast cancer cell lines MCF7 and BT474. J Proteome Res 3:1278-1283
34. Pedram A, Razandi M, Levin E (2006) Nature of functional estrogen receptors at the plasma membrane. Mol Endocrinol 20:1996-2006
35. Nakhla AM, Romas NA, Rosner W (1997) Estradiol activates the prostate androgen receptor and prostate-specific antigen secretion through the intermediacy of sex hormone binding globulin. J Biol Chem 272:6838-6841
36. Singh M, Setalo G Jr, Guan X, Warren M, Toran-Allerand CD (1999) Estrogen-induced activation of mitogen-activated protein kinase in cerebral cortical explants: convergence of estrogen and neurotrophin signaling pathways. J Neurosci 19:1179-1188
37. Filippi S, Luconi M, Granchi S, Vignozzi L, Bettuzzi S, Tozzi P, Ledda F, Forti G, Maggi M (2002) Estrogens, but not androgens, regulate expression and functional activity of oxytocin receptor in rabbit epididymis. Endocrinology 143:4271-4280
38. Wyckoff MH, Chambliss KL, Mineo C, Yuhanna IS, Mendelsohn ME, Mumby SM, Shaul PW (2001) Plasma membrane estrogen receptors are coupled to endothelial nitric-oxide synthase through Galpha(i). J Biol Chem 276:27071-27076
39. Kelly MJ, Qiu J, Wagner EJ, Ronnekleiv OK (2002) Rapid effects of estrogen on G protein-coupled receptor activation of potassium channels in the central nervous system (CNS). J Steroid Biochem Mol Biol 83:187-193
40. Razandi M, Oh P, Pedram A, Schnitzer J, Levin ER (2002) Estrogen receptors associate with and regulate the production of caveolin: Implications for signaling and cellular actions. Mol Endocrinol 16:100-115
41. Wong CW, McNally C, Nickbarg E, Komm BS, Cheskis BJ (2002) Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade. Proc Natl Acad Sci 99:14783-14788
42. Song RX, Barnes CJ, Zhang Z, Bao Y, Kumar R, Santen RJ (2004) The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor alpha to the plasma membrane. Proc Natl Acad Sci 101:2076-2081
43. Marquez D, Lee J, Lin T, Pietras R (2001) Epidermal growth factor receptor and tyrosine phosphorylation of estrogen receptor. Endocrine 16:73-81
44. Pietras R, Arboleda J, Reese D et al (1995) HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10:2435-2446
45. Kim HP, Lee JY, Jeong JK, Bae SW, Lee HK, Jo I (1999) Non-genomic stimulation of nitric oxide release by estrogen is mediated by estrogen receptor alpha localized in caveolae. Biochem Biophys Res Commun 263:257-262
46. Benten WP, Stephan C, Lieberherr M, Wunderlich F (2001) Estradiol signaling via sequestrable surface receptors. Endocrinology 142:1669-1677
47. Pietras RJ, Szego C (1984) Specific internalization of estrogen and binding to nuclear matrix in isolated uterine cells. Biochem Biophys Res Comun 123:84-91
48. Hitosugi T, Sasaki K, Sato M, Suzuki Y, Umezawa Y (2007) EGF directs sex-specific steroid signaling through Src activation. J Biol Chem 282:10697-10706
49. Stevis PE, Deecher DC, Suhadolnik L, Mallis LM, Frail DE (1999) Differential effects of estradiol and estradiol-BSA conjugates. Endocrinology 140:5455-5458
50. Harrington WR, Kim SH, Funk CC, Madak-Erdogan Z, Schiff R, Katzenellenbogen JA, Katzenellenbogen BS (2006) Estrogen dendrimer conjugates that preferentially activate extra-nuclear, nongenomic versus genomic pathways of estrogen action. Mol Endocrinol 20:491-502
51. Kim SH, Katzenellenbogen JA (2006) Hormone-PAMAM dendrimer conjugates: polymer dynamics and tether structure affect ligand access to receptors. Angew Chem Int Ed Engl 45:7243-7248
52. Filardo EJ, Quinn JA, Frackelton AR Jr, Bland KI (2002) Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Mol Endocrinol 16:70-84
53. Maggiolini M, Vivacqua A, Fasanella G, Recchia AG, Sisci D, Pezzi V, Montanaro D, Musti AM, Picard D, Ando S (2004) The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17-Estradiol and phytoestrogens in breast cancer cells. J Biol Chem 279:27008-27016
54. Ahola TM, Manninen T, Alkio N, Ylikomi T (2002) G protein-coupled receptor 30 is critical for a progestin-induced growth inhibition in MCF-7 breast cancer cells. Endocrinology 143:3376-3384
55. Thomas P, Pang Y, Filardo EJ, Dong J (2004) Identity of an estrogen membrane receptor coupled to a G-protein in human breast cancer cells. Endocrinology 164:624-632
56. Albanito L, Madeo A, Lappano R et al (2007) G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17β-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells. Can Res 67:1859-1866
57. Vivacqua A, Bonofiglio D, Recchia AG et al (2006) The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17β-estradiol and hydroxytamoxifen in endometrial cancer cells. Mol Endocrinol 20:631-646
58. Sukocheva O, Wadham C, Holmes A et al (2006) Estrogen transactivates EGFR via the sphingosine 1-phosphate receptor Edg-3: the role of sphingosine kinase-1. J Cell Biol 173:301-310
59. Razandi M, Pedram A, Levin ER (2000) Estrogen signals to preservation of endothelial cell form and function. J Biol Chem 275:38540-38546
60. Lu Q, Pallas DC, Surks HK, Baur WE, Mendelsohn ME, Karas RH (2004) Striatin assembles a membrane signaling complex necessary for rapid, nongenomic activation of endothelial NO synthase by estrogen receptor alpha. Proc Natl Acad Sci 101:17126-1731
61. Razandi M, Alton G, Pedram A, Ghonshani S, Webb D, Levin ER (2003) Identification of a structural determinant for the membrane localization of ERα. Mol Cell Biol 23:1633-1646
62. Chambliss KL, Simon L, Yuhanna IS, Mineo C, Shaul PW (2005) Dissecting the basis of nongenomic activation of eNOS by estradiol: role of ER domains with known nuclear functions. Mol Endocrinol 19:277-289
63. Song RX, McPherson RA, Adam L, Bao Y, Shupnik M, Kumar R, Santen RJ (2002) Linkage of rapid estrogen action to MAPK activation by ER alpha-shc association and shc pathway activation. Mol Endocrinol 16:116-127
64. Acconcia F, Ascenzi P, Fabozzi G, Visca P, Marino M (2004) S-palmitoylation modulates human estrogen receptor-alpha functions. Biochem Biophys Res Commun 316:878-883
65. Acconcia F, Ascenzi P, Bocedi A, Spisni E, Tomasi V, Trentalance A, Visca P, Marino M (2004) Palmitoylatin-dependent estrogen receptor (alpha) membrane localization regulation by 17 (beta)-estradiol. Mol Biol Cell 16:231-237
66. Li L, Haynes MP, Bender JR (2003) Plasma membrane localization and function of the estrogen receptor alpha variant (ER46) in human endothelial cells. Proc Natl Acad Sci 100:4807-4812
67. Marquez-Garban D, Chen H-W, Weinberg O, Fishbein M, Pietras R (2005) Palmitoylation and membrane association of estrogen receptors in human breast and non-small cell lung cancer cells. Proceedings Endocrine Society, San Diego, CA, 651 (abstract)
68. Pedram A, Razandi M, Sainson RCA, Kim JK, Hughes CC, Levin ER (2007) A conserved mechanism for steroid receptor translocation to the plasma membrane. J Biol Chem (in press)
69. Zhang Z, Maier B, Santen RJ, Song RX (2002) Membrane association of estrogen receptor alpha mediates estrogen effect on MAPK activation. Biochem Biophys Res Commun 294:926-933
70. Kousteni S, Han L, Chen JR, Almeida M, Plotkin LI, Bellido T, Manolagas SC (2003) Kinase-mediated regulation of common transcription factors accounts for the bone-protective effects of sex steroids. J Clin Invest 111:1651-1664
71. Keshamouni VG, Mattingly RR, Reddy KB (2002) Mechanism of 17-β estradiol-induced Erk 1,2 activation in breast cancer cells. A role for HER-2 and PKC-δ. J Biol Chem 277:22558-22565
72. Kahlert S, Nuedling S, van Eickels M, Vetter H, Meyer R, Grohe C (2000) Estrogen receptor alpha rapidly activates the IGF-1 receptor pathway. J Biol Chem 275:18447-18453
73. Kato S, Endoh H et al (1995) Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270:1491-1494
74. Martin MB, Franke TF, Stoica GE, Chambon P, Katzenellenbogen BS, Stoica BA, McLemore MS, Olivo SE, Stoica A (2000) A role for Akt in mediating the estrogenic functions of epidermal growth factor and insulin-like growth factor I. Endocrinology 141:4503-4511
75. Balasenthil S, Barnes CJ, Rayala SK, Kumar R (2004) Estrogen receptor activation at serine 305 is sufficient to upregulate cyclin D1 in breast cancer cells. FEBS Lett 567:243-247
76. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME (1999) Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96:857-868
77. Zwijsen RM, Wientjens E, Klompmaker R, van der Sman J, Bernards R, Michalides RJ (1997) CDK-independent activation of estrogen receptor by cyclin D1. Cell 88:405-415
78. Lopez GN, Turck CW, Schaufele F, Stallcup MR, Kushner PJ (2001) Growth factors signal to steroid receptors through mitogen-activated protein kinase regulation of p160 coactivator activity. J Biol Chem 276:22177-22182
79. Iwase H (2003) Molecular action of the estrogen receptor and hormone dependency in breast cancer. Breast Cancer 10:89-96
80. Michalides R, Griekspoor A, Balkenende A et al (2004) Tamoxifen resistance by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer. Cancer Cell 5:597-605
81. Yamakawa K, Arita J (2004) Cross-talk between the estrogen receptor-, protein kinase A-, and mitogen-activated protein kinase-mediated signaling pathways in the regulation of lactotroph proliferation in primary culture. J Steroid Biochem Mol Biol 88:123-130
82. Jordan VC (2004) Selective estrogen receptor modulation: concept and consequences in cancer. Cancer Cell 5:207-213
83. Duan R, Xie W, Li X, McDougal A, Safe S (2002) Estrogen regulation of c-fos gene expression through phosphatidylinositol-3-kinase-dependent activation of serum response factor in MCF-7 breast cancer cells. Biochem Biophys Res Commun 294:384-394
84. Pedram A, Razandi M, Aitkenhead M, Hughes CCW, Levin ER (2002) Integration of the non-genomic and genomic actions of estrogen: membrane initiated signaling by steroid (MISS) to transcription and cell biology. J Biol Chem 277:50768-50775
85. Gately S, Li WW (2004) Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Semin Oncol 31:2-11
86. Myers MP, Pass I, Batty IH, Van der Kaay J, Stolarov JP, Hemmings BA, Wigler MH, Downes CP, Tonks NK (1998) The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci 95:13513-13518
87. Liang J, Slingerland JM (2003) Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2:339-345
88. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S (2002) The protein kinase complement of the human genome. Science 298:1912-1934
89. Miki Y, Swensen J, Shattuck-Eidens D et al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66-72
90. Datta SR, Brunet A, Greenberg ME (1999) Cellular survival: a play in three Akts. Genes Dev 13:2905-2927
91. Proud CG (2004) Role of mTOR signalling in the control of translation initiation and elongation by nutrients. Curr Top Microbiol Immunol 279:215-244
92. Plotkin LI, Ignacio Aguirre J, Kousteni S, Manolagas SC, Bellido T (2004) Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of ERK activation. J Biol Chem 280:7317-7325
93. Chen JR, Plotkin LI, Aguirre JI, Han L, Jilka RL, Kousteni S, Bellido T, Manolagas SC (2004) Transient versus sustained phosphorylation and nuclear accumulation of ERKs underlie anti- versus Pro-apoptotic effects of estrogens. J Biol Chem 280:4632-4638
94. Meyer G, Feldman EL (2002) Signaling mechanisms that regulate actin-based motility processes in the nervous system. J Neurochem 83:490-503
95. Simoncini T, Scorticati C, Mannella P et al (2006) Estrogen receptor alpha interacts with Galpha13 to drive actin remodeling and endothelial cell migration via the RhoA/Rho kinase/moesin pathway. Mol Endocrinol 20:1756-1771
96. Kipp JL, Ramirez VD (2001) Effect of estradiol, diethylstilbestrol, and resveratrol on F0F1-ATPase activity from mitochondrial preparations of rat heart, liver, and brain. Endocrine 15:165-175
97. Chen JQ, Delannoy M, Cooke C, Yager JD (2004) Mitochondrial localization of ERalpha and ERbeta in human MCF7 cells. Am J Physiol Endocrinol Metab 286:E1011-1022
98. Yang SH, Liu R, Perez EJ et al (2004) Mitochondrial localization of estrogen receptor beta. Proc Natl Acad Sci 101:4130-4135
99. Pedram A, Razandi M, Wallace D, Levin E (2006) Functional estrogen receptors in the mitochondria of breast cancer cells. Mol Biol Cell 1749:2125-2137
100. Osborne C, Schiff R (2005) Estrogen-receptor biology: continuing progress and therapeutic implications. J Clin Oncol 23:1616-1622
101. Pietras R (2006) Biologic basis of sequential and combination therapies for hormone-responsive breast cancer. Oncologist 11:704-717
102. Acconcia F, Kumar R (2005) Signaling regulation of genomic and nongenomic functions of estrogen receptors. Cancer Lett 238:1-14
103. Weinberg O, Marquez-Garban D, Pietras R (2005) New approaches to reverse resistance to hormonal therapy in human breast cancer. Drug Resist Updat 8:219-233
104. Johnston S, Martin L, Head J et al (2005) Aromatase inhibitors: combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance. J Steroid Biochem Mol Biol 95:173-181
105. Wright C, Nicholson S, Angus B et al (1992) Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Brit J Cancer 65:118-124
106. Borg A, Baldetorp B, Ferno M et al (1994) ErbB2 amplifi-cation is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett 81:137-143
107. Leitzel K, Teramoto Y, Konrad K et al (1995) Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 13:1129-1135
108. Benz C, Scott G, Sarup J et al (1993) Estrogen-dependent, tamoxifen-resistent tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 24:85-92
109. Lipton A, Ali S, Leitzel K et al (2002) Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol 20:1467-1472
110. De Laurentis M, Arpino G, Massarelli E et al (2005) A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res 11:4741-4748
111. Weigel N (1996) Steroid hormone receptors and their regulation by phosphorylation. Biochem J 319:657-667
112. Stoica G, Franke T, Wellstein A et al (2003) Estradiol rapidly activates Akt via the ErbB2 signaling pathway. Mol Endocrinol 17:818-830
113. Fan P, Wang J, Santen RJ, Yue W (2007) Long-term treatment with tamoxifen facilitates translocation of estrogen receptor α out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells. Cancer Res 67:1352-1360
114. Pietras RJ, Marquez DC, Chen H-W et al (2003) Improved antitumor therapy with Herceptin and Faslodex for dual targeting of HER-2 and estrogen receptor signaling pathways in human breast cancers with over-expression of HER-2/neu gene. Breast Cancer Res Treat 82:12-13
115. Ellis M, Coop A, Singh B et al (2003) Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res 63:6523-6531
116. Subbaramaiah K, Howe L, Port E et al (2006) HER-2/neu status is a determinant of mammary aromatase activity in vivo: evidence for a cyclooxygenase-2-dependent mechanism. Cancer Res 66:5504-5511
117. Kinoshita Y, Chen S (2003) Induction of aromatase (CYP19) expression in breast cancer cells through a nongenomic action of estrogen receptor alpha. Cancer Res 63: 3546-3555
118. Masamura S, Santner SJ, Heitjan DF et al (1995) Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J Clin Endocrinol Metab 80:2918-2925
119. Santen RJ, Song RX, Zhang Z et al (2004) Adaptive hypersensitivity to estrogen: mechanism for sequential responses to hormonal therapy in breast cancer. Clin Cancer Res 10:337S-345S
120. Witters I, Kumar R, Chinchilli V, Lipton A (1997) Enhanced antiproliferative activity of the combination of tamoxifen plus HER-2-neu antibody. Breast Cancer Res Treat 42:1-5
121. Kunisue H, Kurebayashi J, Otsuki T et al (2000) Anti-HER-2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER-2. Br J Cancer 82:46-51
122. Nicholson R, Hutcheson I, Harper M et al (2001) Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer. Endocr Relat Cancer 8:175-182
123. Ellis M (2004) Overcoming endocrine therapy resistance by signal transduction inhibition. Oncologist 9:20-26
124. Peralba J, DeGraffenried L, Friedrichs W et al (2003) Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin Cancer Res 9:2887-2892
125. Ferrara N (2005) VEGF as a therapeutic target in cancer. Oncology 69 3:11-16
126. Pietras RJ (2003) Interactions between estrogen and growth factor receptors in human breast cancers and the tumor-associated vasculature. Breast J 9:361-373